Santa Farma İlaç Receives R&D Patent Award

Santa Farma İlaç received the second prize in the 'Number of National Patent Registrations in Drug R&D' category at the Crystal Mortar Awards.

Within the scope of the 13th International Pharmaceutical Chemistry Congress organized by the Association of Chemists, Crystal Mortar Awards were presented to pharmaceutical companies operating in Turkey across various categories, taking into account their R&D activities in 2023.

Santa Farma İlaç, continuing its activities with the mission of 'healthy service to health', was deemed worthy of the second prize in the 'Number of National Patent Registrations in Drug R&D' category under the Crystal Mortar Awards. Santa Farma İlaç, which plays an active role in intellectual property rights and drug development processes, continues to strengthen its strong position in the sector through innovative pharmaceutical R&D work.

"With this prestigious award we received, we have once again proven our leading role in pharmaceutical R&D and patent registration in Turkey," said Ersin Yıldırım, R&D Director at Santa Farma İlaç, continuing as follows:

"We view R&D and innovation activities as one of the most fundamental strategies of our company. We are proud to receive this award as evidence that we continue our commitment to human health with an innovation-based approach and that we add value to our achievements through the national and international patent registrations we have obtained in this process. We will continue to use our experience of over 80 years in the pharmaceutical sector to strengthen human and public health with our 'The Future is Ours' vision."